Prognostic significance of long non-coding RNA five prime to XIST in various cancers

Jian Zhou,Gen Wu,Tang Liu,Junjie Chen,Wanchun Wang,Zhen Zhou,Ziyuan Chen,Yingquan Luo,Tong Wu

doi:10.1186/s12885-021-09161-0

Abstract

BackgroundTo observe the clinicopathological and prognostic value of long non-coding RNA five prime to X inactive specific transcript (lncFTX) in multiple tumors.MethodsEligible studies for lncFTX were identified by searching PubMed, Embase, Web of Science and Cochrane Library databases from inception to December 01, 2020. Stata 12.0 software was used to calculate the odds ratio (OR)/hazard ratio (HR) and 95% confidence interval (95% CI). We used The Cancer Genome Atlas (TCGA) dataset to further investigate the differential expression and prognostic value of lncFTX.ResultsWe included 11 studies involving a total of 1633 patients. The results showed that the expression of lncFTX was positively associated with advanced TNM stage (III-IV versus I-II) (OR = 2.30, 95% CI: 1.74–3.03, P < 0.05), lymph nodes metastasis (OR = 3.01, 95% CI: 2.00–4.52, P < 0.05), distant metastasis (OR = 3.68, 95% CI: 2.13–6.34, P < 0.05), and cancer mortality (HR = 1.83, 95% CI: 1.20–2.81, P < 0.05). However, the expression of lncFTX was not associated with tumor differentiation (poor differentiation versus well or moderate differentiation) and vessel invasion of cancer. Subgroup analysis showed that the higher lncFTX expression was associated with shorter overall survival in cancer patients, regardless of the sample size and cancer type. No publication bias was found, and the sensitivity analysis results suggested that the main findings were robust. Elevated expression and prognostic significance of FTX were confirmed using TCGA dataset.ConclusionsThis study found that the expression of lncFTX was positively associated with advanced tumor node metastasis (TNM) stage, lymph nodes, distant metastasis and, cancer mortality, suggesting that lncFTX might be a potential prognostic biomarker for tumors.

Highlights

Cancer is a leading cause of death worldwide and an important public health problem
Quantitative real-time polymerase chain reaction was used to detect the expression of lncFTX in these included studies. These studies provided the clinicopathological data of cancer patients, which included gender, age, tumor size, tumor differentiation, tumor node metastasis (TNM) stage, vessel invasion, lymph nodes metastasis, distant metastasis, and overall survival
Association between the expression of lncFTX and cancer clinicopathological features As shown in Fig. 2, we found that an elevated expression of lncFTX was significantly associated with more advanced TNM stage (III-IV VS I-II) (OR = 2.30, 95% confidence interval (CI): 1.74–3.03, P < 0.05) (Fig. 2B), greater lymph nodes metastasis (OR = 3.01, 95% confidence interval (95% CI): 2.00–4.52, P < 0.05) (Fig. 2D) and distant metastasis (OR = 3.68, 95% CI: 2.13–6.34, P < 0.05) (Fig. 2E), and shorter overall survival (HR = 1.83, 95% CI: 1.20–2.81, P < 0.05) (Fig. 2F)

Summary

Introduction

Cancer is a leading cause of death worldwide and an important public health problem. In the United States, 606,880 cancer related deaths and 1,762,450 new cancer cases were projected to occur in 2019 [1]. Zhou et al BMC Cancer (2022) 22:61 death [2, 3] there is an urgent need to find biomarkers that can help clinicians diagnose and treat cancers at an early stage [4,5,6]. Long non-coding RNA five prime to X inactive specific transcript (LncRNA) refers to a type of non-coding RNA with a molecular length of more than 200 nucleotides. Some long-chain non-coding RNAs were found that increased significantly in tumor tissues. These data suggest that the LncRNA may be used as a biomarker for cancer screening and a potential target for the evaluation of clinical prognosis in cancer patients [10]. To observe the clinicopathological and prognostic value of long non-coding RNA five prime to X inactive specific transcript (lncFTX) in multiple tumors

Methods

Results

Conclusion